Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
Condition: Breast Cancer Interventions: Device: nonlinear microscopy imaging of excised surgical margins; Procedure: standard lumpectomy without nonlinear microscopy imaging Sponsors: Dana-Farber Cancer Institute; Massachusetts Institute of Technology Not yet recruiting - verified October 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2016 Category: Research Source Type: clinical trials
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Atezolizumab; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Procedure: Lumpectomy; Procedure: Mastectomy; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified August 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2016 Category: Research Source Type: clinical trials
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Atezolizumab; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Procedure: Lumpectomy; Procedure: Mastectomy; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified September 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2016 Category: Research Source Type: clinical trials
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Atezolizumab; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Procedure: Lumpectomy; Procedure: Mastectomy; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified August 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2016 Category: Research Source Type: clinical trials
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Atezolizumab; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Procedure: Lumpectomy; Procedure: Mastectomy; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified September 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2016 Category: Research Source Type: clinical trials
